FOSUN PHARMA
复星医药

2023

1

2

3

4

5

6

2023 1/2

2023 2/2

	2023	2022
	414.00	439.52
	198.05	207.82
	47.8%	*47.3%*
	97.12	91.71
	23.5%	*20.9%*
	24.4%	*26.4%*
	43.75	38.28
	10.6%	*8.7%*
	43.46	43.02

1/2

® **PD-1**

3 ES-SCLC MAA EMA

11 nsNSCLC NDA

2/2

HLX-10 (PD-1)
HLX-22 (HER-2)
ADC
FS-1502 (HER-2 ADC)
HLX-43 (PD-L1 ADC)
HLX-42 (EGFR ADC)

XS-02 (CHK1)
XS-03 (PLK1)
FCN-159 (MEK1/2)
FH2001 (FGFR/VEGFR)

(CD20)
HLX-15 (CD38)

FKC-876 (CD19-CAR-T)
FKC-889 (CD19-CAR-T)
GCK-01 (CAR-NK)

XS-04

VS-S103 (GLP1)

Tenapanor (ESRD-HD)

XH-S004

ET-26 (GABA)

Opicapone (COMT)

FKC-288
(CAR-T)

XH-S003 (Factor B)

13
24

年			

Gland Pharma CDMO 4 Cenexi

10

Intas 4200



5 16 GPO

800

5

Gland Pharma

2

12

Gland Pharma

PD-1

ES-SCLC

PD-1

GS(2016)1666

E
Environmental
Social
ESG
S
G
Governance


3,413
-
1,961

SCLC PD-1

2023 **11.20**

2023 6 **r/r LBCL**

CAR-T

2023	
4	
4	
8	
34	

倍稳®
盐酸凯普拉生片
Keverprazan Hydrochloride Tablets
10mg

拓培非格司亭注射液
2.0mg

一心坦®
100mg
沙库巴曲缬沙坦钠片
Sacubitril Valsartan Sodium Tablets



DAXXIFY
FOR INJECTION

Gland
Pharma







1
2
3

1 2

Sisram

Sisram

100 78%



/

Soprano Titanium Opus

BeautiFill FDA

LipoSense

CellFie

2017

2016 Intuitive Surgical

2017

2019

Xi

2020

200 800

1,700

2021

4,000

2022

31.2

2023

10 *

2024

2024

2023 55

350 3,000

2000 FDA 2023

8,606

76,000

1,420

Ion

2024 3 Ion

*

Ion

Ion

Ion


6,080
9.74% YoY
6,672


1,2
同比减亏4.21亿元
-622
-201


2
2022
2023
同比减亏3.52亿元
-792
-440

亚洲领先水准
医疗集团
多层次保障
保司

1

2

2023 **6,548** * **8**

.

1,750

87.41%

2023

6%

51%

2023

7 **6**


552,148
596,570
9,054
2,101

				阿达木单抗注射液
				 苏可欣® 马来酸阿伐曲泊帕片

				拓培非格司亭注射液

				

				依诺肝素钠注射液 肝素钠注射液
				100mg 沙库巴曲缬沙坦钠片

1/2

			/		IND	1	2	3	NDA
	HLX10[1]	+	PD-1		III 2022 11				
					2022 FDA/EC		2023 1		
				/					
		+ +	PD-1		III 2023 1				
		+	PD-1+VEGF						
		+HLX07	PD-1+EGFR						
		+HLX07 +	PD-1+EGFR +VEGF						
		+HLX208[#]	PD-1+BRAFV600E	BRAFV600E BRAFV600					
	HLX07		EGFR						
	HLX22[#]								
	HLX11	[2]	HER2		III				
	HLX05	[3]	EGFR						
	HLX02	[4]	HER2		FDA 2020				
	FS-1502[#]	-	HER2	HER2					
				HER2					
			PD-1	HER2					

1 KGBio 10 2 Organon 3 4

Accord Cipla Jacobson mAbxience Eurofarma Abbott 5 2023 12 31 #

2/2

			/		
	HLX26	+	LAG-3+PD-1	mCRC	
		+ +			
		-	LAG-3		
	HLX15		CD38		
	HLX51		OX40		
	HLX13		CTLA-4		
	HLX53		TIGIT		
	HLX60	-	GARP		
		+	GARP+PD-1		
	HLX42		EGFR	/	
	HLX43		PD-L1	/	
	VT-101				
	SurVaxM#		Survivin		
	(T)		-	GvHD	
		50R	INSR		
		25R	INSR		
			GLP-1		
			GLP-1		
			INSR		
	HLX04-O[1]		VEGF		
	HLX14	2	RANKL		
	RT002#			GL	
				CD	
	GC101		COL7A1 CGT		



#

2023 12 31

1/2

					IND	1	2	3	NDA
	FCN-437c		CDK4/6	2L					
				1L					
	SAF-189		ALK/ROS1	ALK+					
				ROS1+					
	HLX208#	-	BRAF	LCH	2023 4 LCH ECD NMPA				
				Erdheim-Chester ECD					
			BRAF+PD-1	BRAFV600E BRAFV600					
	FCN-159		MEK1/2	I	2023 7 NMPA II				
					2023 4 NMPA				
	YP01001		VEGFR						
	FCN-338	+	BCL-2						
		-			I				
		-		B	I				
	FH-2001		FGFR/VEGFR						
	XS-03		PLK1	RAS					

2023 12 31 #

2/2

		/		IND	1	2	3	NDA
	#	TPO-R	ITP					
	Tenapanor #	NHE3	CKD					
	Tenapanor #	NHE3	(IBS-C)	I				
	Pretomanid #	-	/ XDR-TB MDR-TB	Pretomanid*				
	OP0595(Nacubactam) # +	-						
	Opicapone #	COMT		Ongentys*				
	Fortacin #	-		*				
	ET-26	-		2023 10	III			
	FCN-159	MEK1/2						
	SZEY-2108	-	CRE	2023 6 NMPA				
	XH-S002	FXIa						
	FCN-016	ROCK		2023 1 NMPA				
	XH-S003	Factor B	IgA	I	2024 3	I		

2023 12 31 #

			IND	1	2	3	NDA

/ T

CHO

VERO
/ / /
mRNA



1/2

4+7		5mg	3	
		10mg	1	
		250mg	3	
		150mg	3	
		2.5mg	3	
		100mg	4	
		40mg	2	
		100mg	3	
		1mg/2mg	3	
		250mg	2	
		10mg	3	
		40mg	5	
	2	10mg	4	
	1	500mg	1	
		200mg	2	
		20mg	5	
		250mg	1	

1 1 2 3 4 5

6

2/2

		#
		50mg
		10ml/3ml
		3ml
		1g/0.25g/0.5g/2g
		0.25g/0.5g/1g
		5ml/10ml/20ml
		150mg

4 LOGO

Fosun Pharma, the Representor or the P.000010733.68 20d/MCID 17/Lang (en-US)>BDC 0.000010729 0 720 405.12 reW* nBT/F2 9.96 Tf1 0 0 1495CID

www.fosunpharma.com